Avid Bioservices, Inc. (CDMO) |
| 12.49 0 (0%) 02-04 16:00 |
| Open: | 12.49 |
| High: | 12.49 |
| Low: | 12.49 |
| Volume: | 0 |
| Market Cap: | 799(M) |
| PE Ratio: | -5.18 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 10.69 |
| Resistance 1: | 10.54 |
| Pivot price: | 10.49 |
| Support 1: | 10.31 |
| Support 2: | 8.58 |
| 52w High: | 12.51 |
| 52w Low: | 5.9 |
Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.
| EPS | 1.200 |
| Book Value | 11.680 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.997 |
| Profit Margin (%) | 59.99 |
| Operating Margin (%) | 86.32 |
| Return on Assets (ttm) | 4.8 |
| Return on Equity (ttm) | 10.1 |
Mon, 11 May 2026
Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer - PR Newswire
Tue, 24 Feb 2026
Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California - PR Newswire
Tue, 16 Sep 2025
Avid Bioservices Welcomes Kenneth Bilenberg as new CEO - BioSpace
Wed, 22 Jan 2025
Avid Bioservices (CDMO) Started a Sale Process - Yahoo Finance
Tue, 10 Dec 2024
Avid Bioservices, Inc. Reports Second Quarter Fiscal 2025 Financial Results and Announces Merger Agreement with GHO and Ampersand Capital Partners - Quiver Quantitative
Thu, 07 Nov 2024
Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition - MedCity News
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |